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Abstract
Background: High-mobility group protein box1 (HMGB1) is a pivotal factor in the development and progression of
many types of tumor. Its role in hepatocellular carcinoma (HCC), and especially its correlation with intratumoral and
peritumoral macrophage infiltration, remains obscure. We analyzed the potential roles and prognostic value of
HMGB1 and explored the correlation between HMGB1 and macrophage infiltration in HCC using clinical samples.
Methods: We reviewed clinicopathological and follow-up data on a cohort of 149 patients with HCC complicated
with Hepatitis B-related cirrhosis. We measured the expression of HMGB1 and CD68 in tumoral and peritumoral
liver tissues after curative resection and assessed the impacts of the tumor-associated macrophage (TAM) count
and HMGB1 expression on clinicopathologic characteristics, overall survival (OS), and recurrence-free survival (RFS).
Results: Ninety-four of the patients had elevated tumoral HMGB1 expression and 59 of the patients had elevated
peritumoral HMGB1 expression, compared to only 4 patients with elevated peritumoral HMGB1 expression in 36
pateints with Hepatitis B virus (HBV)-negative HCC without liver cirrhosis (p < 0.001). The peritumoral HMGB1 expression
levels were correlated with tumor invasiveness, BCLC stage, and recurrence. The degree of TAM infiltration was higher
in peritumoral tissues with high HMGB1 expression than in peritumoral tissues with low HMGB1 expression (p < 0.001).
There was no significant difference in TAM infiltration between tumoral tissues with high and low HMGB1 expression.
Kaplan-Meier analysis showed that intratumoral HMGB1 overexpression was associated with poor OS, but not with RFS.
High peritumoral HMGB1expression and TAM count, which correlated positively with tumor size and BCLC stage,
were independent prognostic factors for OS (p < 0.001 and p = 0.017, respectively) and RFS (p = 0.002 and p = 0.024,
respectively). Multivariate analyses indicated peritumoral HMGB1 expression (p = 0.014) and TAM count (p = 0.037), as
well as tumor differentiation (p = 0.026), to be independent significant prognostic factors for RFS.
Conclusions: High HMGB1 expression in peritumoral liver tissues correlated with peritumoral macrophage infiltration
and had prognostic value in HCC, suggesting that peritumoral HMGB1 might show promise as a new biomarker to
predict HCC progression.
Keywords: High-mobility group protein box1, Tumor-associated macrophage, Hepatocellular carcinoma,
Liver cirrhosis, Prognosis
* Correspondence: jiangrunde@163.com; zzl25808@gmail.com;
jiangrunde@163.com
†Equal contributors
1Department of General Surgery, Qilu Hospital, Shandong University, 107
Wenhua West Road, Jinan 250012, China
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zhang et al. BMC Cancer  (2016) 16:880 
DOI 10.1186/s12885-016-2883-z
Background
Hepatocellular carcinoma (HCC), the fifth most com-
mon cancer worldwide, ranks as the third leading cause
of cancer death globally [1, 2]. Although surgical resec-
tion and liver transplantation are the main modalities of
curative treatment to provide long-term survival for pa-
tients with HCC, a high recurrence rate after surgery is
a major problem [3]. Despite progress in molecular
biology and cancer therapy in recent years, the overall
prognosis for HCC remains dismal, which is mainly
attributed to the high incidences of local recurrence,
distant metastasis, and therapy resistance [4]. Recently,
the tumor microenvironment, which plays an important
role in the initiation, progression, recurrence, and me-
tastasis of various tumors, has been intensively studied.
Changes of the tumor microenvironment have been
closely correlated with cancer-mediated inflammation.
Furthermore, an inflammatory response is detectable in
tumors that is not causally related to inflammation [5].
High-mobility group box 1 (HMGB1), an evolutionarily
conserved, chromatin-binding protein [6, 7], is normally
located in the nucleus, where it acts as a DNA chaperon
by regulating transcription, replication, recombination, re-
pair, and genome stability [8]. In response to some stimuli,
such as hypoxia, it can be released into the extracellular
environment [9]. Necrotic cells, particularly those derived
from cancer tissues, passively release HMGB1, mediating
local inflammation and cancer development [10]. HMGB1
overexpression has been observed in the cells of some
cancers such as breast cancer [11], colon cancer [12],
gastrointestinal stromal tumors [13], and liver cancer [9].
Through the binding with its receptors, such as RAGE or
TLRs, HMGB1 has been associated with tumor-cell sur-
vival, progression, and metastasis [14, 15]. Extracellular
HMGB1 displays cytokine activity and can promote
inflammation by activating macrophages, which repre-
sent the main type of inflammatory cells infiltrating
tumors [16, 17].
Tumor-associated macrophages (TAMs) are mainly
polarized towards an M2 phenotype, which has been
associated with angiogenesis, metastasis, and poor prog-
nosis [18]. Accumulating evidence has demonstrated an
association between TAM density and unfortunate prog-
nosis in HCC [19–21]. An abundance of CD68 macro-
phage infiltration in peritumoral liver tissues, but not in
tumors, was previously associated with poor prognosis
in HCC [22]. Exposure of macrophages to HMGB1
exerts proinflammatory effects by inducing the TLR4-
dependent and CD14-dependent release some inflamma-
tory cytokines such as monocyte chemotactic protein 1,
interferon gamma-induced protein 10, and macrophage
inflammatory protein 1α [23–25].
HMGB1 is associated with clinicopathologic features
and has prognostic significance for overall and disease-
free survival in patients with HCC after curative hepa-
tectomy [26, 27]. To the best of our knowledge, there
Fig. 1 Representative immunostaining for CD68 in peritumoral a and tumoral c liver tissue and for HMGB1 in peritumoral b and tumoral d liver
tissue. Scale bar, 100 um
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are no previous reports of an association between
HMGB1 expression and TAM infiltration in tumors and
peritumoral tissues in HCC. We therefore aimed to as-
certain whether HMGB1 expression is correlated with
TAM infiltration in tumors and peritumoral tissues and
to determine whether HMGB1 expression correlates
with prognosis in patients with HCC.
Methods
Patients, specimens, and follow-up
We collected tumoral and peritumoral specimens from
149 patients (82 men and 67 women; mean age:
67.5 years) with pathologically confirmed HCC compli-
cated with cirrhosis who underwent curative liver resec-
tion at our institute (Liver Cancer Institute, Zhongshan
Hospital, Fudan University). The median tumor size was
4.2 cm (range: 1.5–11.0 cm). Another 36 patients with
HBV-negative HCC without liver cirrhosis were also
collected to examine the expression of HMGB1 in
peritumoral liver tissues. An experienced pathologist ex-
amined haematoxylin and eosin-stained sections from
each tumor sample to confirm the histological diagnosis
and assess the tumor content. Histological diagnoses in-
cluding the tumor differentiation and encapsulation were
made according to the guidelines proposed by the World
Health Organization. Clinical profiles and follow-up
records after surgical resection were obtained from
the medical records of Zhongshan Hospital of Fudan
University.
The follow-up procedures were described in our previ-
ous reports [28]. Briefly, the patients were monitored by
abdominal ultrasonography, serum a-fetoprotein (AFP),
and chest radiography with an interval of 2–6 months
according to the postoperative time. If recurrence was
suspected, computed tomography scanning or magnetic
resonance imaging was performed immediately. Treat-
ment modalities after relapse were administered accord-
ing to a uniform guideline. Overall survival (OS) and
recurrence-free survival (RFS) were defined as the inter-
val between surgery and death or disease recurrence, re-
spectively. If recurrence was not diagnosed, the patients
were censored on the date of death or last follow-up.
The study was approved by the Qilu Hospital of
Shandong University Ethics Committee, and written
informed consent for recording and analysis of data was
obtained from all patients.
Immunohistochemical staining and macrophage
quantification
HMGB1 expression in paired tumoral and paratumoral
liver tissues from the patients was examined by immuno-
histochemistry. We used CD68 to mark the macrophages
in the tissues. Using the semiquantitative scale described
previously [29], the HMGB1protein expressions were
scored by multiplying the proportion of positive cells and
intensity. The proportion of positive cells ranked as fol-
lows: 1(≤25 %), 2 (26–50 %), 3 (51–74 %), and 4 (≥75 %).
The intensity of nuclear or cytoplasmic staining was evalu-
ated as follows; no staining/background of negative controls
(score = 1), weak staining detectable above background
(score = 2), moderate staining (score = 3), and intense stain-
ing (score = 4). The index was obtained by multiplying the
percentage and intensity scores, the score ≤ 8 was defined
as low expression, and the score >8 was defined as high ex-
pression. Meanwhile, the HMGB1protein expression and
CD68+ cells density were also quantified with the method
described in our previous study [28]. Under high-power
magnification (200×), photographs of two representative
fields of each punch were captured by a computerized
image system composed of a Leica CCD camera DFC 500
connected to a Leica DM IRE2 microscope and Leica
Qwin Plus v3 software (Leica Microsystems Imaging
Solution, Cambridge, UK). We measured the area of posi-
tive staining in pixels using Image-Pro Plus v6.2 software
Table 1 Correlation of HMGB1 expression with known
clinicopathologic characteristics in peritumoral liver tissue and
in tumor tissue in 149 HCC cases
Peri-HMGB1 expression Intra-HMGB1 expression
Features Low High p value Low High p value
Age
≤ 55 55 36 32 59
> 55 35 23 0.563 23 35 0.277
Gender
Male 53 29 36 46
Female 37 30 0.159 19 48 0.055
a-Fetoprotein
≤ 400 ng/ml 67 43 37 73
> 400 ng/ml 23 16 0.489 18 21 0.116
Tumor size (mean ± SD, cm)
≤ 5 cm 75 47 47 75
> 5 cm 15 12 0.360 8 19 0.262
Encapsulation/none
Complete 38 36 22 52
Incomplete 52 23 0.019 33 42 0.051
Tumor differentiation
I-II 70 45 43 72
III-IV 20 14 0.491 22 22 0.496
BCLC stage
I 60 48 35 73
II-III 30 11 0.036 20 21 0.049
Recurrence
Yes 27 34 22 39
No 63 25 0.001 33 55 0.022
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(Media Cybernetics, Bethesda, MD). The expression of
HMGB1protein and the densities of CD68 staining were
expressed as the ratio of the positively stained area to the
total area of each photograph.
Statistical analysis
We performed all statistical analyses using SPSS16.0 for
Windows (SPSS). Correlations between clinicopathologic
characteristics and HMGB1 expression were assessed
using the χ2 test. We used the Pearsonχ2 test or the
Fisher exact test to compare qualitative variables and the
Student t test or the Spearman correlation test to com-
pare quantitative variables. We used a Kaplan-Meier
analysis to determine the survival curves and the log-
rank test to compare the survival curves between sub-
groups. In the survival analyses, we used death from
disease and recurrence/metastasis as the endpoints for
OS and RFS, respectively. We tested the associations
between the variables and survival using univariate and
multivariate analyses with the Cox proportional hazard
model. The difference between survival curves was ana-
lyzed by the log rank test. p < 0.05 was considered to be
statistically significant.
Results
Correlation between HMGB1 expression and
clinicopathologic characteristics
HMGB1 immunohistochemical expression showed pre-
dominant cytoplasmic staining and little nuclear staining
in the tumoral and paratumoral liver tissues (Fig. 1).
High HMGB1 expression was detected in 94 (63.1 %) of
the tumor tissues and in 59 (39.6 %) of the paired para-
tumoral tissues. The correlations between clinicopatho-
logic characteristics and HMGB1 expression in the
tumoral and paratumoral liver tissues are shown in
Table 1. High peritumoral HMGB1 expression was posi-
tively correlated with recurrence (p = 0.001), tumor
Fig. 2 Immunohistochemical staining demonstrated that showed high expression of HMGB1 was associate with high invasiveness of HCC.
Representative immunostaining for HMGB1 in tumor with encapsulation (a) and without encapsulation (b)
Table 2 Correlation of CD68+ macrophage with known
clinicopathologic characteristics in peritumoral liver tissue and
in tumor tissue in 149 HCC cases
Peri-CD68 expression Intra-CD68 expression
Features Low High p value Low High p value
Age, year
≤ 55 35 56 43 48
> 55 32 26 0.034 30 28 0.358
Gender
Male 40 42 39 43
Female 27 40 0.192 34 33 0.412
a-Fetoprotein (ng/ml)
≤ 400 46 64 55 55
> 400 21 18 0.134 18 21 0.411
Tumor size (mean ± SD, cm)
≤ 5 53 69 61 61
> 5 14 13 0.280 12 15 0.379
Encapsulation/none
Complete 38 36 39 35
Incomplete 29 46 0.082 34 41 0.231
Tumor differentiation
I-II 51 64 60 55
III-IV 16 18 0.466 13 21 0.109
BCLC stage
I 54 54 49 59
II-III 13 28 0.033 24 17 0.105
Recurrence
Yes 36 41 37 40
No 31 41 0.387 36 36 0.471
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encapsulation (p = 0.019) (Fig. 2), and advanced BCLC
stage (p = 0.036). In contrast, intratumoral HMGB1 ex-
pression had no statistically significant correlation with
tumor encapsulation (Table 2).
Peritumoral HMGB1 expression was upregulated in
HBV-positive HCC, but not in HBV-negative HCC
We examined the expression of HMGB1 in peritumoral
liver tissues from 36 patients with HBV-negative HCC
without liver cirrhosis. Only four of those samples
displayed high HMGB1 expression, while the other 32
displayed low HMGB1 expression. Overall, the peritu-
moral expression of HMGB1 was lower in the pa-
tients with HBV-negative HCC than in the patients
with HBV-positive HCC (p = 0.004), which might be
attributed to the background of cirrhosis (Additional
file 1: Figure S1).
HMGB1 expression was associated with peritumoral TAM
infiltration
Because HMGB1 could activate human peripheral blood
monocytes and induce the production of proinflam-
matory cytokines, we examined whether macrophage
infiltration was associated with HMGB1expression in
tumoral or peritumoral liver tissues. As shown in Fig. 3,
there was significantly more TAM infiltration in the
peritumoral liver tissues with high HMGB1 expression
than in the peritumoral liver tissues with low HMGB1
expression. TAM infiltration was high in all of the tumor
tissues, however, regardless of the HMGB1 expression
level, and there was no significant difference in TAM in-
filtration in the tumor tissues based on HMGB1 expres-
sion. As shown in Fig. 3, HMGB1 overexpression was
correlated positively with CD68+ macrophage density in
the peritumoral liver tissues (p < 0.001).
Prognostic relevance of HMGB1 expression and TAM
infiltration in HCC
We examined whether the expression of HMGB1 in tu-
moral and peritumoral liver tissues had value in predicting
clinical outcomes or prognosis in HCC. The Kaplan-Meier
analysis (log-rank test) showed that HMGB1 overex-
pression in both the peritumoral liver tissues and the
tumor tissues was associated with worse OS (p < 0.001 and
p = 0.028, respectively). Only HMGB1 overexpression in
the peritumoral liver tissues was associated with worse
RFS, however (p = 0.002). The TAM count in the peritu-
moral liver tissues was significantly associated with both
OS and RFS (p = 0.017 and p = 0.024, respectively), whereas
the TAM count in the tumor tissues was associated with
neither OS nor RFS (Fig. 4). We also performed the ana-
lysis of prognosis and HMGB1. 149 patients were catego-
rized into two groups according to their survival time. Of
the two groups, good prognosis,who survived longer than
median survival time(MST), were involved in group One,
and another group was matched with bad prognosis who
survived shorter than MST. We compared the HMGB1
level in two groups. Peritumoral HMGB1 expression in
group of bad prognosis was significantly higher than those
in group of good prognosis, while intratumoral HMGB1
expression in group of bad prognosis was modestly higher
than those in group of good prognosis (Fig. 5).
For further analysis, we investigated whether the
HMGB1 expression in the peritumoral or tumoral liver
tissues was an independent prognostic variable. We con-
structed a Cox proportional hazards model using estab-
lished prognostic factors, HMGB1 expression, and TAM
count. The univariate analysis revealed that tumor size,
tumor differentiation, BCLC stage, peritumoral and
intratumoral HMGB1 expression, and peritumoral TAM
count, but not intratumoral TAM count, were independ-
ent prognostic factors for OS. In addition, patients with
Fig. 3 Correlation of HMGB1 expression with CD68+ macrophage infiltration in peritumoral and tumoral liver tissues in patients with HCC.
Two-demissional plot showed HMGB1 overexpression correlated positively with CD68+ macrophage density in peritumoral liver tissue (a), while
modest correlation was found between HMGB1 expression and CD68+ macrophage density in tumor tissues (b)
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Fig. 4 (See legend on next page.)
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high peritumoral HMGB1 expression had a worse RFS
prognosis than those with low peritumoral HMGB1 ex-
pression (p = 0.002). Univariate analyses also indicated
tumor size, tumor differentiation, BCLC stage, peritu-
moral HMGB1 expression, and peritumoral TAM count
to be prognostic factors for RFS.
Multivariate analyses indicated peritumoral HMGB1
expression, peritumoral TAM count, and BCLC stage to
be independent prognostic factors for OS. In addition,
multivariate analyses indicated peritumoral HMGB1 ex-
pression, peritumoral TAM count, and tumor differenti-
ation to be independent prognostic factors for RFS. The
multivariate analyses showed no significant association
between intratumoral TAM count and either RFS or OS
(Table 3).
Discussion
Previously, we found that the density of peritumoral
CD68+ cells was associated with poor RFS and OS [28].
Therefore, we further analyzed the potential roles and
prognostic value of HMGB1 and explored the correl-
ation between HMGB1 and macrophage infiltration in
patients with HBV-related HCC complicated with liver
cirrhosis. High HMGB1 expression in peritumoral liver
tissues was correlated with peritumoral macrophage in-
filtration, was significantly associated with recurrence,
incomplete tumor encapsulation, and advanced BCLC
stage, and predicted poorer survival for patients with
HCC with liver cirrhosis after curative hepatectomy.
HMGB1 is constitutively expressed in the nucleus of
tumor cells and can be released by inflammatory cells
and by tumor cells [30]. Once released, HMGB1 works
as a damage-associated molecular pattern molecule,
binding to receptors such as RAGE and TLRs [31].
There is a growing body of evidence that HMGB1 plays
pivotal roles in the development and progression of
many types of tumors, including HCC [32]. Most of that
evidence is based on the direct effects of HMGB1 on
tumor cells [33]. The contribution of immune cells in
the tumor microenvironment, and particularly the
correlation with macrophages, remains elusive. In the
immune system, HMGB1 increases the secretion of
inflammatory cytokines (IL-1β, IFN-γ, and TNF-α) [34]
and acts as a late inflammatory cytokine by activating
macrophages in response to LPS [35]. HMGB1 could en-
hance tumor-cell invasion and promote angiogenesis by
supporting the protumoral functions of TAMs by a
RAGE-dependent mechanism [36]. Thus, HMGB1 could
act as an autocrine/paracrine tumor-growth factor in can-
cer. A compelling body of evidence has shown the contri-
bution of HMGB1 to the malignant progression of HCC,
and high HMGB1 expression predicts a poor prognosis
for patients with HCC [27, 37]. To the best of our know-
ledge, an association between HMGB1 expression and
TAM infiltration has not been reported in HCC.
We found that the HMGB1 expression in peritumoral
and tumoral liver tissues was correlated with the TAM
count and with several conventional clinicopathological
parameters. It is therefore worth determining whether
HMGB1 expression and TAM count are accurate and
reliable prognostic factors in HCC. HMGB1 expression
showed predominant cytoplasmic staining and sparse
(See figure on previous page.)
Fig. 4 Cumulative overall survival (OS) and recurrence-free survival (RFS) curves of patients with high and low expression of HMGB1 (panels a, b,
e, and f) and high and low densities of CD68+ cell infiltration (panels c, d, g, and h) in tumoral and peritumoral liver tissues. In peritumoral liver
tissues, the expression of HMGB1 and the density of CD68+ cells were both associated with poor OS and RFS (panels a, c, e, and g). In tumor
tissues, the expression of HMGB1 was associated with poor OS but not RFS (panels b and f), while the density of CD68+ cells could not discriminate
patients with different OS or RFS (panels d and h)
Fig. 5 Peritumoral HMGB1 expression in group of bad prognosis (Survival < MST) was significantly higher than those in group of good prognosis
(Survival > MST) (a), while intratumoral HMGB1 expression in group of bad prognosis was modestly higher than those in group of good
prognosis (b)
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nuclear staining in tumor and paratumoral liver tissues.
HMGB1 expression in the peritumoral liver tissues was
strongly correlated with higher histological grades and
tumor invasiveness, whereas HMGB1 expression in the
tumors was only correlated marginally with recurrence
and higher BCLC stage. High HMGB1 expression in the
peritumoral liver tissues was correlated with peritumoral
macrophage infiltration, whereas that in the tumors
was not.
Jiang et al. found that HMGB1 overexpression in
tumor tissues, rather than that in paratumoral and nor-
mal tissues, was correlated with advanced TNM stage,
vascular invasion, and capsule invasion [27]. Our results
also demonstrated a correlation between HMGB1 over-
expression in HCC tumor tissues and poor OS. In
contrast to previous results, however, our study also in-
dicated HMGB1 overexpression in paratumoral tissues
that was correlated positively with macrophage infiltra-
tion and negatively survival. The fact that our study
included only patients with HCC complicated with liver
cirrhosis might account for the discrepancy with other
studies.
HMGB1 acts as a molecular link between hepatocyte
death and liver fibrogenesis [38]. Its release has been
observed from the hepatocytes of patients suffering from
various kinds of liver diseases [39] and was involved in
the activation of hepatic stellate cells, which increases
extracellular matrix overproduction [40]. Moreover, the
serum HMGB1 concentration increased significantly in
chronic CCl4 intoxication-induced hepatic fibrogenesis
[41]. We identified peritumoral HMGB1 overexpression
in only 11 % of patients with HBV-negative HCC
without liver cirrhosis, probably because of the close
association between HMGB1 expression and liver fibro-
sis, suggesting that HCC and liver fibrosis are both influ-
enced by HMGB1-mediated macrophage stimulation.
Further studies are warranted to investigate of the
role and regulation of HMGB1 in liver cirrhosis and
HCC.
Conclusions
In summary, we observed high HMGB1 expression
levels in peritumoral liver tissues correlated with peritu-
moral macrophage infiltration. Peritumoral HMGB1 ex-
pression had prognostic value in HCC with cirrhosis,
suggesting that peritumoral HMGB1 might show prom-
ise as new biomarker to predict HCC progression and
potential therapeutic targets in HCC and liver fibrosis.
Additional file
Additional file 1: Figure S1. Immunohistochemical staining
demonstrated that peritumoral expression of HMGB1 was higher in the
patients with HBV-positive HCC (A, B) than in the patients with HBV-negative
HCC (C, D). (TIF 16359 kb)
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Tumor differentiation, III–IV vs. I–II 0.026 1.217(0.715-2.072) 0.468 0.015 1.157(1.103-2.584) 0.026
BCLC stage, C vs. B vs. A 0.003 1.783(1.265-2.564) 0.027 0.003 1.768(0.949-3.295) 0.073
Recurrence, yes vs. no 0.062 NA NA 0.052 NA NA
Peritumoral HMGB1, high vs. low 0.001 1.872(1.148-3.053) 0.009 0.002 1.697(1.035-2.783) 0.014
Intratumoral HMGB1, high vs. low 0.028 1.270(0.745-2.166) 0.462 0.060 NA NA
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